Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges - PubMed
4 days ago
- #HIV
- #antiretroviral therapy
- #adherence
- Randomized trial of long-acting injectable cabotegravir plus rilpivirine for HIV patients with adherence challenges.
- Participants with inadequate adherence to oral ART received adherence support before randomization.
- 306 participants were randomized to either cabotegravir-rilpivirine injections or standard oral ART.
- Cabotegravir-rilpivirine showed superiority, with 22.8% regimen failure vs. 41.2% in standard care at 48 weeks.
- Adverse events were similar between groups (43.5% vs. 42.4%).
- Resistance mutations developed in 2 participants per group with virologic failure.
- Long-acting injectable therapy reduced risk of regimen failure in adherence-challenged HIV patients.